Brightsurf Science News & Current Events

June 05, 2004
Novel therapeutic bortezomib moves to phase II trial in lung cancer patients
A three-drug combination including the novel molecularly targeted agent bortezomib, the first drug in its class, proved well-tolerated and showed promising efficacy in patients with advanced non-small cell lung cancer, according to phase I trial results.

ASCO late breaker - breast cancer- dose dense
New data presented at the 2004 meeting of the American Society of Clinical Oncology suggest that a chemotherapy regimen including ELLENCE (epirubicin) may significantly improve survival in breast cancer patients at highest risk of recurrence.

Avastin-Tarceva combo provides 'one-two' punch against lung cancer
Results of the first clinical trial to combine two new targeted cancer drugs suggest that the combination may provide a powerful

Global study shows new breast cancer drug extends patients' overall survival
Breast cancer patients with advanced disease live longer when treated with a new drug, gemcitabine, in combination with paclitaxel, a traditional drug, according to results of a landmark global phase III study presented today at the American Society of Clinical Oncology (ASCO) annual meeting.

2004 BP Conservation Programme winners pave the way for protecting wildlife
Twenty-nine young teams working on a range of globally threatened species and habitats from 23 countries across the world will be awarded a total of $600,000 this year by the BP Conservation Programme - the most awarded in the programme's 14-year history.

Researchers identify genetic markers to predict response to chemotherapy for colorectal cancer
One of the most common challenges facing oncologists today is determining the best course of treatment for their patients--one that would be effective and have the fewest possible side effects.

Recurrent endometrial cancer with a molecular alteration may respond to targeted therapy
The first test of a targeted therapy to treat recurrent endometrial (uterine) cancer will open in June at M.

Gene mutation and use of certain antidepressants may decrease effects of breast cancer drug
Researchers from the Johns Hopkins Kimmel Cancer Center, Indiana University and the University of Michigan have found that some women have a gene mutation that may decrease the effectiveness of tamoxifen, a commonly used breast cancer drug.

Investigational drug shows promise in kidney cancer patients
Interim phase-II trial results of an investigational drug known as BAY 43-9006 (sorafenib) demonstrate a significant and lasting benefit for a subset of patients with advanced renal cell cancer, researchers from the University of Chicago report at ASCO.

Cancer patients' genes may influence how they experience fatigue and quality of life
Is there a relationship between a cancer patient's genetic makeup and quality of life?

Study finds Velcade major improvement over standard therapy for relapsed multiple myeloma patients
Early results from a major, international Phase III clinical trial decisively show that recurrent multiple myeloma is more effectively treated with the drug bortezomib (trade name: Velcade TM) than with dexamethasone, a drug that for decades has been the standard therapy for relapsed disease, researchers at Dana-Farber Cancer Institute report.

Researchers identify two potential protein targets for new drug therapies for pancreatic cancer
Researchers at Fox Chase Cancer Center in Philadelphia have identified two proteins in pancreatic cancer that may be potential targets for new, more specific drug therapies against this deadly disease.

Prostate cancer pill may stave off disease and ease pain
Recent clinical studies led by Johns Hopkins Kimmel Cancer Center researchers have found that a drug called atrasentan reduces the risk by 20 percent that cancer will progress in men with advanced hormone-resistant prostate cancer.

Promising new treatment for aggressive kidney cancer
A new multi-targeted anticancer drug called SU11248 has shown very promising results in the treatment for metastatic renal cell cancer, one of the most chemotherapy resistant of all cancers.

Breakthrough drug Tarceva delivers significant survival benefits in lung cancer
5 June 2004, Basel - Roche OSI Pharmaceuticals and Genentech today announced that their investigational drug TarcevaTM (erlotinib) achieved a significant 42.5% improvement in median survival compared to placebo in patients with advanced non-small cell lung cancer (NSCLC).

When combining new oral anti-cancer agents with standard chemotherapy, timing may be crucial
Timing may be everything when it comes to combining the new-generation oral, molecularly targeted anti-cancer agents with standard chemotherapy drugs.

Taxotere (R) offers significant survival benefits for head and neck cancer patients
Aventis (NYSE: AVE) announced that a phase III trial using Taxotere (R) (docetaxel) Injection Concentrate added to a standard therapy for nonresectable locally advanced squamous cell carcinoma of the head and neck was presented at the American Society of Clinical Oncology (ASCO) meeting.

Lung cancer patients in Japan, United States react differently to the same chemotherapy regimen
A chemotherapy regimen commonly used to treat non-small cell lung cancer is both more effective and more toxic in Japanese patients than in American patients.

Attitudes may deter African Americans from receiving surgery for non-small cell lung cancer
Do African Americans with early-stage non-small cell lung cancer (NSCLC) have a lower overall survival rate than Caucasians with the disease because they have less access to adequate medical care, or because they are less likely to agree to lung surgery when offered? is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to